-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: Luminex Platform Features in Detail
Author:
InnoModels
Release time:
2024-05-13
With the rapid development of life science technology, there is a growing demand for efficient, accurate and high-throughput biomolecular detection platforms for researchers. Against this backdrop, the Luminex platform of InnoModels Biotechnology has emerged and occupied a pivotal position in life science research with its unique advantages. In this article, we will analyze the features of the Luminex platform in detail, and reveal how it has revolutionized traditional biomolecular detection methods.
The core technology of the Luminex platform lies in the application of fluorescence-encoded magnetic beads/microspheres. These microspheres are fluorescently encoded to carry multiple antibodies or gene probes specific for different biomolecules at the same time. This design allows the Luminex platform to accurately quantify up to 2-500 different biomolecules in a single tube, greatly improving detection efficiency.
The platform integrates a variety of advanced technologies such as flow principles, laser analysis, and high-speed digital signal processing to realize parallel analysis of multiple indicators. Laser irradiation of the fluorescence on the magnetic beads can quickly identify the captured antibody labeled by the beads, and then determine the detection items corresponding to the beads. This design not only improves the accuracy of the test, but also makes the operation process easier, greatly reducing the experimental cost and time cost.

The Luminex platform offers significant advantages in assay performance. Measurement results are similar to those of traditional methods such as ELISA in terms of accuracy, precision, and sensitivity. In addition, the Luminex platform has a wider linear range, which further enhances the reliability of the assay results.
It is worth mentioning that the Luminex platform excels in multiplexed detection. By freely combining different fluorescence-encoded magnetic beads, researchers can analyze multiple target molecules simultaneously in a single experiment. This multi-detection capability not only reduces the consumption of biological samples, but also allows for more accurate analysis of correlations between multiple target molecules.
In addition, the Luminex platform has excellent application scalability. In addition to immunoassay, nucleic acid research, enzyme analysis, etc., the platform can also be applied to pathogen detection and typing, HLA typing, miRNA expression profiling, transcription factor research, and many other applications. This makes the Luminex platform have a wide range of application prospects in basic life science research and medical diagnostic technology development.
In conclusion, with its unique fluorescence-encoded magnetic bead technology, its ability to analyze multiple indicators in parallel, and its wide range of applications, InnoModels' Luminex platform has demonstrated strong competitiveness in the field of biomolecular testing. With the continuous development and improvement of the technology, it is believed that the Luminex platform will bring more breakthroughs and innovations to life science research and medical diagnosis in the future.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd